SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w
in combination with Apatinib at one dose (375mg). Comparison of 3 different dose schedules in
subjects with extensive-stage disease small cell lung cancer. SHR-1210 is a humanized
monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective
Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI).
The study is composed of two parts. Part 1 of the study will determine the safety and
tolerability of SHR-1210 in combination with Apatinib in first 6 subjects of each arm. Part 2
of the study will determine the safety and efficacy of SHR-1210 in combination with Apatinib
in 45 subjects of each arm.